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Abstract: Atypical adenomatous hyperplasia (AAH) is a putative
precursor of bronchioloalveolar carcinoma (BAC) and adenocarci-
noma of the lung, developing from terminal respiratory unit cells.
AAH and BAC lesions typically present as ground-glass opacities at
spiral chest computed tomography. Epidermal growth factor recep-
tor polysomy/mutations, conferring higher sensitivity to Gefitinib,
are frequent in BAC but less common in AAH. We describe an
interesting case of disseminated AAH showing a sustained remis-
sion under Gefitinib therapy.
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CASE REPORT
In September 2001, a 62-year-old female smoker of 76packs/year, without history of previous cancer or respira-
tory diseases, was enrolled in a chest computed tomography
(CT)-screening trial. In October 2002, the patient underwent
right upper lobe lobectomy for stage IA adenocarcinoma. The
patient resumed smoking 1 year after surgery. In November
2004, chest CT revealed disseminated bilateral ground-glass
opacity (GGO), ranging from 5 to 20 mm (Figure 1A). Each
CT section was graded separately according to the percentage
of the area showing GGO abnormalities. The mean extent of
GGO, calculated with the method of visual score, reached
20% in three zones (aortic arch, carina, and 2 cm above the
diaphragm) of each lung. Lung function tests showed mod-
erate obstructive lung impairment. Left video-assisted thora-
coscopy revealed multiple subcentimetric nodules, involving
the whole parenchyma. Excision of one partially solid lesion
of 9 mm in the upper lobe showed bronchioloalveolar carci-
noma (BAC) at frozen section, and two additional lesions
were resected from upper and lower lobes. The final patho-
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FIGURE 1. A, Chest computed tomography as on Novem-
ber 2004 showing disseminated bilateral ground-glass opac-
ity, ranging from 5 to 20 mm. B, Chest computed tomogra-
phy after 12 months of Gefitinib therapy showing complete
resolution of ground-glass opacity.
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logic report confirmed nonmucinous BAC in the first speci-
men and atypical adenomatous hyperplasia (AAH) in the
other two biopsies (Figures 2A,B). Molecular analysis of the
epidermal growth factor receptor (EGFR) gene (exons 18–
21) showed no mutations in BAC and AAH lesions, but
fluorescence in situ hybridization analysis detected high lev-
els of EGFR polysomy (defined when more than two specific
signals for both EGFR genes and chromosome 7 centromeric
probes are present per nucleus) in BAC, and disomy (defined
when two copies of both EGFR and chromosome 7 centro-
meric probes are observed per nucleus) in all AAH specimens
(Figures 3A,B). K-ras analysis showed TGT mutation only in
BAC (codon 12 TGT). As the patient refused cytotoxic
chemotherapy, she was started on Gefitinib treatment on
December 2004, which was well tolerated, without diarrhea
or significant cutaneous toxicity. On December 2005, chest
CT showed a complete resolution of parenchymal infiltrates
(Figure 1B). After 4 years of Gefitinib therapy at full dose,
chest CT confirmed persistence of radiologic remission.
DISCUSSION
Complete remission of BAC have been reported after
Gefitinib therapy.1–3 To our knowledge, however, this repre-
sents the first case of prolonged remission of pathologically
proven disseminated AAH associated with BAC. The long-
term disease-free survival presented here shows that concur-
rent disomy of EGFR gene and absence of K-ras mutation
can predict response to Gefitinib in AAH lesions, even in the
absence of EGFR mutations.
Our experience suggests that long-term administration
of Gefitinib might be effective in the management of AAH
and multifocal BAC presenting as diffuse GGO, when fluo-
rescence in situ hybridization or molecular testing are indic-
ative of sensitivity.
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FIGURE 2. A, Pathologic features of nonmucinous bronchi-
oloalveolar carcinoma (hematoxylin-eosin stain, 20). B,
Atypical adenomatous hyperplasia (hematoxylin-eosin stain, 20).
FIGURE 3. A, bronchioloalveolar carcinoma specimen with
epidermal growth factor receptor (EGFR) gene (in red) and the
centromeric probe for chromosome 7 (in green). Five/seven
signals for each gene were detected per nucleus. B, In ad-
enomatous hyperplasia specimen, the normal disomic pat-
tern for EGFR gene was detected (two EGFR and centromeric
signals/nucleus).
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